Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Endometrial Neoplasms 1Brain Neoplasms 1

Interventions

Gemcitabine 47Cisplatin 32pembrolizumab 28Paclitaxel 13Docetaxel 13avelumab 12Mitomycin 12atezolizumab 11Nivolumab 11Cystectomy 10Carboplatin 9durvalumab 7Sunitinib 7apaziquone 6Doxorubicin 6BCG Vaccine 65-aminolevulinic acid hexyl ester 6Vinblastine 5Radiation 5Platinum 5Methotrexate 5Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5Taxes 4Standard of Care 4Sorafenib 4Radiotherapy 4Fluorouracil 4Erlotinib Hydrochloride 41,2-diaminocyclohexaneplatinum II citrate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urinary Bladder Neoplasms × ferumoxtran-10 × Clear all
NCT00147238 2012-08-07

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 3 charts
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡